Caraco says it's unlikely to resume manufacturing at its Detroit facility before April, as it had estimated earlier. Following a review with its GMP consultants on the remediation steps completed since it entered into a consent decree with the FDA in September 2009, and those still pending, the generics maker has revised its restart estimate. Remediation continues, the company says, but it can't predict when manufacturing and distribution operations will resume. Caraco release